Blog icon


Dr Puttick completed a PhD in Chemistry at the University of Nottingham in 2012 where his study was focussed on the use of nuclear magnetic resonance spectroscopy to understand the spatial organisation of ionic liquids. Following his PhD, he moved to the University of Cambridge as a Research Fellow focussed on the discovery of magnetic resonance imaging biomarkers of neurodegeneration in Huntingtons Disease.

He moved to Australia in 2013 to take up a position as a Research Fellow at the University of Queensland focussed on the development of theranostics for primary brain cancers. In this position he developed a keen interest in the field of nuclear medicine and has developed a portfolio of active research in this field.

Dr Puttick moved to CSIRO in 2018 to drive a program of research in theranostic development. He now manages a $12.5M research portfolio leading 24 scientists across 7 projects focussed on; discovery of diagnostic biomarkers; discovery and engineering of biological ligands; design and development of diagnostic devices; clinical evaluation of biologic therapeutics and production of medical radioisotopes.

To date, Dr Puttick has published 42 journal articles, 1 book chapter and filed 1 patent and his research has attracted ~$10.5M in research grant funding and industry investment.

Other Interests

Dr Puttick is a keen woodworker and woodturner

Academic Qualifications

  • 2008

    MSci Chemistry
    The University of Nottingham

  • 2012

    The University of Nottingham

Professional Experiences

  • 2011-2012

    Research Fellow
    The University of Cambridge

  • 2013-2018

    Research Fellow
    The University of Queensland


  • 2014-2014

    The University of Queensland Early Career Researcher Grant - "Imaging Hypoxia in Glioblastoma Multiforme" - $20,500

  • 2015-2017

    Cure Brain Cancer Foundation Innovation Grant - " Developing novel, EphA2 targeted PET molecular imaging technology for glioma" - $219,711

  • 2017-2020

    CSIRO R+ - "Increasing Therapeutic Delivery to Brain Tumours through In Vivo Click Chemistry" - $315,000

  • 2018-2018

    Avners Pancreatic Foundation Grant - "A Novel Theranostic for Pancreatic Cancer" - $100,000

  • 2019-2021

    CSIRO R+ - "Reducing the Impact of Brain Trauma through Prevention of Glial Scar Formation" - $315,000

  • 2019-2021

    CSIRO R+ - "Theranostics and Diagnostics for Precision Oncology" - $315,000

  • 2019-2021

    NHMRC Project - "Nanomedicine Strategies for Early Detection and Treatment of Brain Metastases" - $667,521

  • 2020-2020

    Avners Pancreatic Cancer Foundation - "Development of a Theranostic for Pancreatic Cancer" - $100,000

  • 2020-2021

    Mark Hughes Foundation - "The Development and Clinical Translation of Blood-Based Diagnostics for Brain Cancer" - $195,250

  • 2020-2022

    CSIRO R+ - "Developing a Microfluidics Platform for Dose-on-Demand Peptide Receptor Radionuclide Therapy (PRRT)" - $336,000

  • 2020-2024

    MRFF Emerging Priorities - "A New Targeted Radio-Imaging Agent to Guide Targeted Therapy for Epithelial Ovarian Cancer" - $1,893,306

  • 2020-2020

    Innovation Connections - "Development of NanoYeast for Diagnostic Devices" - $98,518

  • 2020-2020

    US NIH Rapid Acceleration of Diagnostics - "Point-of-Care Antigen Testing for COVID-19" - $1,410,000